Researchers will first compare liquid with tissue-based tumor profiling before implementing it as a way to enroll patients into the targeted drug trials.
The firm's diagnostics and genomics group saw a 13 percent year-over-year revenue increase in the first quarter.
The company received Chinese regulatory approval for a lung cancer assay last year and plans to seek approval for a liquid biopsy test this year.
The MammaSeq assay comprises 79 genes and 1,369 mutations in breast cancer that could be used as potential downstream therapeutic targets.
Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.
The American Society of Breast Surgeons updated consensus guidelines to recommend multigene panel testing for patients with cancer, including those who were tested many years ago.
While the study showed initial promise, further work will be necessary to clarify its performance for various clinical indications.
The company plans to use the funds to support development of an early cancer detection test and expansion of its CDx sales force.
The US Court of Appeals upheld a previous ruling by the International Trade Commission that found Oxford Nanopore's products do not infringe on PacBio's patents.
The team plans to launch an RNA-seq diagnostic test out of the SickKids clinical laboratory in one year to complement clinical exome sequencing.
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
In Science this week: the synthetic genetic system hachimoji, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.